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ABSTRACT 
Objective: This study was designed to investigate some possible therapeutic mechanisms of pentoxifylline and sildenafil in the treatment of 
colorectal carcinoma induced by 1, 2 dimethylhydrazines in rats.  
Methods: Rats were allocated into seven groups, negative control, colon cancer induced by 1,2,dimethylhydrazine, 5-fluorouracil (5-FU) (50 
mg/kg)-treated, pentoxifylline (PTX) (50 mg/kg)-treated, sildenafil (0.7 mg/kg)-treated groups; the two other groups set as colon cancer induced 
group treated with PTX (50 mg/kg) plus 5-FU(50 mg/kg) and sildenafil (0.7 mg/kg) plus 5-FU (50 mg/kg), respectively.  
Results: Biochemical results revealed significant elevation of serum carcinoembryonic antigen (CEA) levels, carbohydrate19-9 antigen (CA19-9) as 
colon cancer specific antigen markers; and a significant decrease in scaspase-3 (CASP3) as a marker for apoptosis, in the cancer-induced group 
compared to negative control group. Cancer-induced rats treated with 5-FU, with PTX or sildenafil showed a significant decrease in serum CEA and 
CA19-9 levels and a significant increase in CASP3 levels compared to cancer induced group. Furthermore, plasma levels of CEA and CA19-9 in 5-FU 
plus pentoxifylline and in 5-FUplus sildenafil groups were significantly decreased and plasma levels of CASP3 in 5-FU plus PTX, 5-FU plus sildenafil 
groups were significantly increased with respect to 5-FU treated group. 
Conclusion: Results of the present study suggest a good therapeutic approach of the PDE inhibitors, PTX and sildenafil for intervention against 
progressive colon cancer with special reference to the induction of apoptosis in colon cancer cells. 




Colorectal carcinoma (CRC) is a major cause of cancer morbidity and 
mortality. Nearly 150,000 US residents diagnosed annually with 
CRC, and approximately one-third of CRC patients die from the 
disease [1]. Only about 20% of CRC cases have a familial basis; some 
are associated with well-defined syndromes, such as hereditary non-
polyposis colorectal cancer (HNPCC) and familial adenomatous 
polyposis (FAP) [2]. However, the largest fraction of CRC cases has 
been linked to environmental causes rather than heritable genetic 
changes. Risk factors include environmental and food-borne 
mutagens, pathogens, and chronic intestinal inflammation that 
precede tumor development. The lifetime risk of CRC in the average-
risk person, defined as without personal history or family history of 
CRC and above the age of 50, is 5%–6% [3]. Risk increases at young 
age (15–30%) if a first-degree relative has a history of CRC, and in 
some of the well-described inheritable cancer syndromes (e. g. 
HNPCC, FAP) to very high degree (>80%) [4]. 
Improvements in anticancer treatment and screening efforts that lead to 
early detection and removal of polyps lead to decrease in the incidence 
and mortality rate of CRC. The widely used chemotherapeutic agents for 
the treatment of CRC include 5-fluorouracil (5-FU) in combination with 
folinic acid (FA) and oxaliplatin [5]. It was reported that the combination 
of chemotherapy increase response rates (35%–53%) and prolonged 
progression-free survival (5–8 mo) and overall survival (14–18 mo) [6, 
7]. In addition, agents targeting the vascular endothelial growth factor 
(VEGF) (e. g. bevacizumab) or epidermal growth factor receptor (EGFR) 
(e. g. cetuximab) pathways increase the efficacy of cytotoxic 
chemotherapy that cause increase in the survival and have led to newer 
method that are now the first line therapy used for the treatment of 
metastatic CRC [8]. 
Despite current therapies, 40% to 50% of CRC patients who undergo 
curative surgery ultimately relapse and die of metastatic disease [9]. 
CRC remains a genetic disease made the understanding of the 
underlying molecular mechanisms of CRC are the main pathway for 
prevention, prediction and prognosis. 
Phosphodiesterases (PDEs) enzymes are responsible for the breakdown 
of the intracellular second messenger's cyclic guanosine monophosphate 
(cGMP) and cyclic adenine monophosphate (cAMP) by catalyzing the 
hydrolysis of the 3’-5’ phosphodiester bond, result in the production of 
the inactive 5’ nucleotides [10]. All mammalian PDEs have a catalytic site 
with a segment of 250-300 amino acids in the carboxyl-terminal portion 
of the protein (20-45% homology between gene families, 70-80% 
homology within gene families)[11]. Different gene families could be 
differentiated according to specific property, such as sensitivity to 
specific inhibitors, substrate affinities, biophysical and biochemical 
properties, and mechanisms of regulation.  
Increased PDE5 expression occurs in various carcinomas, including 
metastatic breast, urinary bladder, and non-small cell lung cancers 
[12-14]. Developments of human oral squamous cell carcinoma 
(OSCC) result from increased PDE5 expression [15]. An increase in 
the level of cGMP-PDEs has been approved in various cell lines 
arises from bladder cancer (HTB-76, HT1376), breast cancer (MCF-
7, HTB-26, and MDA-MB-468), colonic adenocarcinomas (HT29, 
HCT-116, SW480, and T84) and some chronic lymphocytic leukemia 
cells (CLL) [16]. These findings suggest that PDE5 may have a role in 
carcinoma, and the antineoplastic action may result from inhibiting 
the activity of such enzyme. Evaluation, the anticancer effect of 
sildenafil and other PDE5 inhibitors, carried out in multiple 
carcinomas and cancer cell lines. For example, vardenafil and 
sildenafil each may terminate tumor cell growth and induce caspase-
dependent apoptosis of B-cell in (CLL) cells in vitro [17]. Exisulind, 
the non-specific PDE5 inhibitor, selectively induce the apoptosis of 
various breast cancer, human prostate, and colon cells. Furthermore, 
the effects of exisulind were not mediated through their increase in 
prostaglandin levels, p53, cell cycle arrest, or cyclooxygenase 
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inducing actions [18]. Therefore, in light of the potential 
involvement of these enzymes in tumorigenesis, the effects of 
various PDEs need to be evaluated in vivo. 
Pentoxifylline (PTX) was reported to increase blood flow by 
decreasing fibroblast proliferation, inhibiting platelet aggregation, 
decreasing plasma fibrinogen concentrations and increasing 
erythrocyte deformability [19]. Its primary mechanism of action is 
believed to be non-specific inhibition of phosphodiesterases (PDEs), 
leading to accumulation of cyclic adenosine monophosphate (cAMP) 
which, in erythrocytes, increases deformability, and in platelets, 
inhibits aggregation [20]. The suggested dose of PTX is 400 mg, 
taken orally, three to four times a day (or 1,200 mg to 1,600 mg per 
day), a therapeutic dose for intermittent claudication. PTXs utility as 
a palliative therapy in the cancer patient and may have a promising 
effect in relieving some of the toxicities associated with various 
radio and chemotherapies including cachexia, retinopathy, 
myelopathy, oral and intestinal mucositis, pulmonary fibrosis, and 
proctitis/enteritis/mastitis [21]. The palliative dose of PTX in cancer 
treatment is similar to the recommended dose for the intermittent 
claudication and it is equally well tolerated. It believed that PTXs 
hemorheological effects play a significant role in its palliative utility, 
in addition to attenuating TNF-α; though specific mechanisms are 
mostly unknown [22]. 
Sildenafil was an oral phosphodiesterase inhibitor specific to isoform 
type 5 (PDE5) with selectivity for cyclic guanosine monophosphate 
(cGMP) [23, 24]. Nitric oxide (NO) stimulates the enzyme guanylate 
cyclase (GC) to convert guanosine triphosphate (GTP) to cGMP, with 
high levels of cGMP being responsible for the relaxation of smooth 
muscle [25]. Thus, sildenafil enhances the actions of the endogenous 
NO-cGMP pathway, by mediating the elevation of cGMP levels due to 
inhibiting its degradation by PDE5 [26, 27]. Due to the localization of 
PDE5 in the corpus cavernosum, sildenafil was successfully used in the 
treatment of erectile dysfunction, and pulmonary arterial 
hypertension where it relaxes the arterial wall, leading to decreased 
pulmonary arterial resistance and pressure [28]. 
Carcinoembryonic antigen (CEA) is a complex, highly glycosylated 
glycoprotein belonging to the immunoglobulin superfamily and it is 
highly expressed during fetal development. In adult tissues, CEA is 
more limited in its expression but is present in epithelial and goblet 
cells in the colon, mucous neck cells, pyloric mucous cells in the 
stomach, squamous epithelial cells of the tongue, esophagus and 
cervix, secretory epithelial cells in sweat glands and epithelial cells 
of the prostate. Such antigen is typically located on the apical side of 
cells in the colon; however, malignant colon cancer cells may have 
no basal lamina and no polarity and CEA, therefore, distributed 
around the cell surface. It believed that this contributes to the 
increased levels of CEA found in the serum of cancer patients [29]. 
Carbohydrate antigen 19-9 (CA 19-9) is a glycolipid, which primarily 
synthesized by normal human pancreatic and biliary ductular cells. 
In addition, CA 19-9 can synthesize by gastric, colonic, endometrial 
and salivary epithelia [30, 31]. Like many of the other tumor 
markers examined, it hypothesized, that CA 19-9 may play a role in 
cell adhesion. This is based on the function of CA 19-9 as a ligand for 
the adhesion molecule E-selectin [32]. CA 19-9 used together with 
CEA for both diagnosis and follow-up of colorectal and 
gastrointestinal cancers in which the majority of colorectal 
carcinoma cells produce and release CEA and CA19-9 into systemic 
circulation. In clinical practice, those both CEA & CA19-9 remain the 
most frequently used tumor markers for colorectal cancer [33, 34]. 
CA 19-9 monitoring has been recommended for early detection of 
tumor recurrence after its surgical resection [34]. 
Cyclic guanosine monophosphate (cGMP) signaling was emerging as 
important intracellular signaling molecules in cancer treatment. It 
observed that PKG expression was lower in many tumors compared 
to the normal one. It also been demonstrated that apoptosis and 
growth inhibition were mediated by the activation of PKG, in 
addition to the inhibitor of cancer cell migration in human cancer 
cells [35]. These findings are very clinically pertinent because they 
confirm a role for PKG in cancer and provide a novel target for 
therapy. Thus, the aim of the current study was to elucidate the 
possible anti-tumorigenic properties of the two PDE inhibitors, 
pentoxifylline and sildenafil against colorectal cancer by using 
experimentally rats induced with colorectal carcinoma. 
MATERIALS AND METHODS  
Reagents 
Standard assay rat’s kits (CEA, CA19-9 and CASP3) were obtained 
from Elabscience Biotechnology, (USA). 
Drugs and chemicals: 1,2 Dimethylhydrazines was obtained from 
Tokyo Chemical industry (TCA) chemicals, (Japan); 5-fluorouracil 
from Flakon, Turkey; pentoxifylline from Sukhtain Pharmaceutical 
product, (Jordan) and sildenafil from Drug Industries and Medical 
Appliances (SDI), Samarra/Iraq. 
Animals 
Forty-nine white Albino rats of both sexes, weighing 150-200 gm 
were utilized in this study; they were obtained from and maintained 
in the Animal House of the Pharmacy College, the University of 
Baghdad under conditions of controlled temperature. The animals 
were fed commercial pellets and tap water ad libitum. The study was 
approved by the Scientific and the Ethical Committees of the College 
of Pharmacy, University of Baghdad. 
Induction of colon cancer by 1, 2 Dimethyl hydrazine (DMH) 
dihydrochloride  
After the acclimatization period and for induction of colon cancer, 
rats (n = 42) received a dosage of 30 mg/kg body weight DMH 
(dissolved freshly in 0.9 % NaCl solution) subcutaneously (Sc) once 
in a week for 12 w. Healthy control rats (n=7) were given 
intraperitoneal (IP) dose of saline alone [36]. 
Experimental protocol 
The animals used in this study were allocated into seven groups as 
follow:  
Group I: Seven rats received IP dose of normal saline and this group 
served as a negative control. 
Group II: Seven rats received Sc dose of DMH for 12 w. This group 
served as positive control of colorectal carcinoma. 
Group III: Seven rats treated with IP dose of five-fluorouracil (5-FU) 
(50 mg/kg) daily for fourteen days after induction of colorectal 
carcinoma with DMH [37]. 
Group IV: Seven rats treated with IP dose of PTX (50 mg/kg) daily 
for fourteen days after induction of colorectal carcinoma with DMH. 
This dose has been shown to be sufficient to elicit an increase in the 
relative perfusion of subcutaneous redundancy improvement factor-
1 (RIF-I) tumors [38]. 
Group V: Seven rats treated with IP dose of sildenafil (0.7 mg/kg) 
daily for fourteen days after induction of colorectal carcinoma with 
DMH [39]. 
Group VI: Seven rats treated with IP dose of sildenafil (0.7 mg/kg) 
plus 5-FU (50 mg/kg) daily for fourteen days after induction of 
colorectal carcinoma with DMH.  
Group VII: Seven rats treated with intraperitoneal doses of PTX (50 
mg/kg) plus 5-FU (50 mg/kg) daily for fourteen days after induction 
of colorectal carcinoma with DMH.  
At the end of the experimental period (14 w), all the animals were 
sacrificed after euthanization with diethyl ether anesthesia 24 h 
later, blood sample were collected from each rat withdrawn from 
carotid artery at the neck into labeled centrifuging tubes and 
allowed to clot for 20 min at room temperature.  
Biochemical analysis 
The serum was separated by centrifugation at 3000 rpm for 20 min 
for assessments of biochemical parameters: rat carcinoembryonic 
antigen (CEA), rat carbohydrate antigen 19-9 (CA19-9) and rat 
caspase-3 (CASP3) antigen. The blood samples were immediately 
collected from the carotid artery. 
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Data were expressed as mean± standard deviation (SD) of samples. 
The statistical significance of the differences among various groups 
was determined by one-way analysis of variance (ANOVA). Differences 
were considered statistically significant for p-value<0.05. 
RESULTS 
Serum levels of CEA in 5-FU (50 mg/kg), PTX (50 mg/kg), sildenafil 
(0.7 mg/kg), 5-FU (50 mg/kg) plus PTX(50 mg/kg) and 5-FU(50 
mg/kg) plus sildenafil (0.7 mg/kg) groups were significantly 
decreased compared with the positive control group (1.453±0.2843, 
1.587±0.4890, 1.584±0.7187, 0.6186±0.3291 and 0.6543±0.3720 vs 
2.519±0.5207ng/ml), respectively (table 1). Furthermore, serum 
levels of CEA in 5-FU (50 mg/kg) plus PTX (50 mg/kg) and 5-FU (50 
mg/kg) plus sildenafil (0.7 mg/kg) groups were significantly 
decreased with respect to 5-FU (50 mg/kg)-treated group 
(0.6186±0.3291 and 0.6543±0.3720 vs 1.453±0.2843ng/ml), (table 1). 
Table 1 also showed that, in colorectal carcinoma induced rats 
(positive control) there was significantly increased (P<0.05) in 
serum levels of carbohydrate antigen 19-9 (CA19-9) compared with 
the negative control groups, the levels being (10.21±3.747 
vs1.104±0.4289KU/l). 
Serum levels of CA19-9 in 5-FU(50 mg/kg)-, PTX(50 mg/kg)-, 
sildenafil (0.7 mg/kg)-, 5-FU(50 mg/kg) plus PTX(50 mg/kg)-and 5-
FU(50 mg/kg) plus sildenafil (0.7 mg/kg)-treatedgroups were 
significantly decreased compared with the positive control group 
(5.486±1.235, 7.171±1.518, 6.443±2.700, 3.086±1.745 and 
1.800±0.8327 vs 10.21±3.747KU/l), respectively. 
Furthermore, serum levels of CA19-9 in 5-FU (50 mg/kg) plus PTX 
(50 mg/kg)-and 5-FU (50 mg/kg) plus sildenafil (0.7 mg/kg)-treated 
groups were significantly decreased with respect to 5-FU (50 
mg/kg)-treated group (3.086±1.282 and1.800±0.8327 vs 
5.486±1.235KU/l). 
Regarding Caspase-3 (CASP3), table 1 illustrated that in colorectal 
carcinoma induced rats (positive control) there was a significant 
decrease in the serum levels of caspase-3 (CASP3) (P<0.05) 
compared with the negative control group (1.429±0.3861 
vs4.129±1.050KU/l). 
Serum levels of CASP3 in 5-FU (50 mg/kg) plus PTX (50 mg/kg) and 
5-flurouracil (50 mg/kg) plus sildenafil (0.7 mg/kg) groups were 
significantly increased compared with the positive control group 
(5.129±1.720 and 5.057±0.3720 vs 1.429±0.3861KU/l), 
respectively. 
Furthermore, serum levels of CASP3 in 5-FU (50 mg/kg) plus PTX 
(50 mg/kg) and 5-FU(50 mg/kg) plus sildenafil (0.7 mg/kg) groups 
were significantly increased with respect to 5-FU (50 mg/kg) 
treated group (5.129±1.720 and 5.057±1.652 vs 1.429±0.3861KU/l). 
 
Table 1: Effects of treatment on carcinoembryonic antigen, Carbohydrate antigen 19-9 and Caspase-3 (CASP3) levels in rats' groups 
Groups of rats N=7/each group CEA levels (ng/ml) CA 19-9 levels (KU/l) CASP3 levels (KU/l) 
Negative-Control (normal saline) 0.8414±0.2905 1.104±0.4289 4.129±1.050 
Positive-Control (1, 2 
dimethyl hydrazine) 
 2.519±0.5207* 10.93±2.079 * 1.429±0.3861 * 
5-Flurouracil-treated (50 mg/kg)  1.453±0.2843 5.486±1.235 *a 2.429±1.334 a 
Pentoxifylline-treated (50 mg/kg) 1.587±0.4890 7.171±1.518 *a 3.286±1.698 a 
Sildenafil-treated (0.7 mg/kg) 1.584±0.7187 6.443±6.754 *a 2.557±1.708 a 
Pentoxifylline (50 mg/kg) plus 5-
Flurouracil (50 mg/kg) 
0.6186±0.3291 3.086±1.282 ab 5.129±1.720 ab 
Sildenafil (0.7 mg/kg) plus 5-Flurouracil 
(50 mg/kg) 
ab 
0.6543±0.3720 1.800±0.8327 ab 5.057±1.652 ab ab 
Each value represents mean±standard deviation (SD). CEA: Carcinoembryonic Antigen, CA 19-9: Carbohydrate Antigen 19-9, CASP3: Caspase-3,*: 
Significantly different (P<0.05) with respect to the negative control group, a= significant difference with respect to the positive control treated 
group, b= significant difference with respect to the 5-FU treated group, N = number of animals. 
 
DISCUSSION 
Acting as second messengers between an extracellular signal and its 
elicited intracellular response, the cyclic nucleotides, cAMP and 
cGMP, serve as important signal transduction molecules which in 
turn may regulating a number of physiological processes [40]. Both 
the nucleotide signaling has been shown to have negative effects on 
cell growth and survival, depending on the cell type, extracellular 
environment, stimulus, and subcellular localization [41, 42]. In 
contrast, it has been shown that dysregulation of cyclic nucleotide 
signaling has been reported in various malignancies suggesting that 
alteration of these pathways may play an important role in 
tumorigenesis [43, 44]. 
In the current study, a preliminary trial was carried out to examine 
the ability of cGMP and cAMP whether or not to serve as a growth 
inhibitory signal in human colon cancer cells and that selective 
inhibition of PDE could serve as a mechanism for chemoprevention by 
selectively activating proapoptotic cGMP and cAMP signaling in tumor 
cells. After induction of colorectal carcinoma with DMH, sildenafil at a 
dose of 0.7 mg/kg and PTX at a dose of 50 mg/kg by i. p. doses for 14 d 
did produce significant changes in the cancer biomarkers serum levels 
(CEA and CA19-9) compared with the positive control group, and 
these changes were represented by a significant reduction in CEA and 
CA19-9 levels in pentoxifylline and sildenafil groups as compared with 
the positive control group (table 1). 
Cancer biomarkers have become an important tool in the treatment 
of cancer patients, particularly in the monitoring of patients during 
and post treatment. Oncofetal antigens, also occasionally referred to 
as carcino fetal antigens, are markers that are expressed both during 
malignancy and neonatal development, but tend to be absent or 
present in low concentrations in normal adult tissues. This link 
between cancer and early development is not surprising, as many of 
the processes that contribute to cancer progression are also crucial 
to early development, namely, cell proliferation and cell 
differentiation [45]. Carcinoembryonic antigen (CEA) describes a set 
of highly related glycoproteins involved in cell adhesion. It is 
normally produced in GI tissue during fetal development, but the 
production stops before birth. Therefore, CEA is usually present only 
at very low levels in the blood of healthy adults. However, the serum 
levels may be raised in some types of cancer which means that it can 
be used as a tumor marker in clinical tests. CEA are glycosyl 
phosphatidyl inositol (GPI) cell surface anchored glycoproteins 
whose specialized sialon fucosylated glycoforms serve as functional 
colon carcinoma L-selectin and E-selectin ligands, which may be 
critical to the metastatic dissemination of colon carcinoma cells [46-
48]; where, CA19-9 is considered as a ligand for the adhesion 
molecule E-selectin [33]. Results of this study confirmed that 
sildenafil-treated group at a dose of 0.7 mg/kg and pentoxifylline at 
a dose 50 mg/kg produced a significant reduction in CA19-9 serum 
levels compared with the positive control group (table 1).  
In the present study, treatment with PTX (50 mg/kg) or with sildenafil 
(0.7 mg/kg) did not show significant changes in the CASP3 serum 
levels compared with the positive control group, this may attribute to 
the larger dose required or longer period of treatment time (table 1). 
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Cancer cells are in unregulated proliferation status and usually lose 
the ability of apoptosis due to certain signaling defects among the 
apoptotic pathway. However, in many cancer cells the apoptotic 
machinery is still intact with the potential for leading cells to death 
upon the induction by some exogenous factors. Therefore, one of the 
most common goals of cancer chemotherapy is to induce apoptosis in 
cancer cells while leaving non-transformed cells unharmed [49, 50]. 
The induction of apoptosis by the PDE5 inhibitors was 
demonstrated to be a complicated process. For example, cGMP-
activated c-Jun NH2-terminal kinase (JNK), inhibited extracellular 
signal-regulated kinases 1/2 (ERK1/2) and regulated p42/p44 
mitogen-activated protein kinase (MAPK) and p21. [51-54]. 
Pentoxifylline and sildenafil may increase the effect of 5-FU activity 
by blocking the substrate efflux activity [P-glycoprotein (P-gp)] of 
multidrug-resistant transporters which considered as a major 
problem in cancer chemotherapy [55, 56]. PTX treatment caused 
significant Pgp down-regulation in these cells via a decrease in the 
transcription of mdr1 [57, 58]. 
Furthermore, it has been suggested that a dose-dependent increase 
in the percentage of apoptotic cells after PTX treatment could be 
mediated by pathways that include cytochrome c release, caspase-3 
activation and poly ADP ribose polymerase (PARP) cleavage which 
was also documented in cutaneous T-cell lymphoma (HuT-78) [59]. 
These results suggested that the effect that PTX exerts on cells is at 
least partially through PTX promotion of apoptosis. Besides, it has 
been demonstrated that PTX had the ability to improve the 
sensitivity of several neoplastic cells to a large group of drugs that 
includes both substrates and non-substrates of P-gp [60-62]. 
Additionally, increasing of cGMP levels via their inhibition of PDE5 
activity, in which the multidrug resistant transporters (ABCC4-and 
ABCC5) mediated efflux of cGMP, thereby increasing the likelihood 
of cGMP-induced activation of protein kinase G (PKG), which may 
produce growth suppression or apoptosis. In addition, PDE5 
inhibition also leads to apoptosis through increased 
phosphorylation of β-catenin and/or MAP kinase/ERK kinase 
(MEKK1)/stress-activated protein kinase/extracellular signal-
regulated kinase kinase (SEK1)/c-Jun N-terminal kinase 1 (JNK1) 
signaling pathways by increased PKG activation through cGMP 
induction. As shown that in a rat brain tumor model, the PDE5 
inhibitors sildenafil and vardenafil increased the transport of 
doxorubicin across blood-brain tumor barrier and enhanced the 
efficacy of chemotherapy [63].  
Tumor cells are also exposed to acute hypoxia caused by the collapse 
of vessels by high interstitial pressure and plugging by blood cells 
[64]. PTX is a unique agent known to reduce blood viscosity by 
increasing the deformability of erythrocytes and preventing their 
cluster formation, and by inhibiting platelet aggregation, thereby 
improving tumour microcirculation [65]. The intended drug was 
found to decrease elevated tumor interstitial fluid pressure (TIFP) 
as well as increase pO2
The apoptotic activity of PDE inhibitors was increased when 
combined with chemotherapeutic drug and this was previously 
proved by several studies that showed that the apoptotic activity of 
exisulind to be beneficial when combined with docetaxel in non-
small cell lung cancer orthotopic lung tumor model [14] or in 
combination with capecitabine in Phase I and II metastatic breast 
cancer [12]. In a rat brain tumor model, the PDE5 inhibitors 
sildenafil and vardenafil increased the transport of doxorubicin 
across blood-brain tumor barrier and enhanced the efficacy of 
chemotherapy [67].  
 in murine fibrosarcoma tumors, indicative of 
increased tumor perfusion [66]. These findings demonstrated a 
significant ability of PTX in increasing oxygenation, systemic drug 
delivery, and ameliorating hypoxia in solid tumors. 
Sildenafil produced penile vasodilation and reduced tumor hypoxia 
in squamous carcinoma of the penis, when it was used as 
radiosensitizers [68]. PDE5 inhibitor’s radio-sensitization 
mechanism may be due to increased perfusion of blood in the penile 
structure, leading to cGMP-induced relaxation in the corpus 
cavernosum, which reduces hypoxia and thus increase 
radiosensitivity. 
Pentoxifylline can prevent the phosphorylation of serines 32 and 36 
of nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor (IκB), which sequesters NF-κB in the cytoplasm and 
prevents activation of target genes [69,70]. The nuclear factor-kappa 
B (NF-κB) transcription factor plays an important role in tumor cell 
growth, proliferation, invasion, and survival. In this respect, NF-κB 
can activate antiapoptotic genes such as Bcl-2, Bcl-XL, and survivin, 
affecting chemotherapy efficiency, even if the chemotherapy itself or 
the radiotherapy itself can activate the NF-κB factor [71], and it was 
found that PTX in combination with antitumor drugs such as 
adriamycin and cisplatin-induced in vitro and in vivo a significant 
increment of apoptosis in fresh leukemic human cells [72], murine 
lymphoma models [73], and cervical cancer cells [74]. Similar results 
have also been observed with PTX in other studies [59]. 
CONCLUSION 
According to the results obtained from this study it could be 
concluded that, this study broaden the current understanding of the 
involvement of cGMP and cAMP-degrading PDE isozymes inhibitors, 
PTX and sildenafil, in colon tumorigenesis in which PDE had been 
demonstrated to be crucial for colon tumor cell growth and survival. 
We believed that safer and more efficacious agents for colorectal 
cancer can be developed through targeting PDE, which could have 
the potential to make a significant impact on the prevention and 
treatment of this malignant disease for which there is a great unmet 
medical need in which the treatment effects mainly depended on the 
induction of apoptosis in cancer cells. 
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